Observational study of cenegermin for the treatment of limbal stem cell deficiency associated with neurotrophic keratopathy.

ABSTRACT:

Background

Neurotrophic keratopathy (NK) and limbal stem cell deficiency (LSCD) have high morbidity and require aggressive management to prevent permanent vision loss. Cenegermin, a recombinant human nerve growth factor, was approved by the Federal Drug Administration in 2018 for the treatment of NK.

Objectives

To determine the efficacy and safety of cenegermin in the treatment of LSCD associated with NK.

Design

Prospective cohort study.

Methods

Patients diagnosed with LSCD and NK who had failed conventional treatment were enrolled in this prospective open-label study. Patients were treated with cenegermin for 8 weeks. The primary objective was to determine whether the area of abnormal epithelium decreased following treatment. Corneal sensation, visual acuity (

SUBMITTER: Arboleda A 

PROVIDER: S-EPMC9638689 | biostudies-literature | 2022 Jan-Dec

REPOSITORIES: biostudies-literature